Canary Global has been accepted into Canada’s SR&ED program which aims to encourage R&D work conducted for the advancement of scientific knowledge or for the purpose of achieving a technological advancement.
Canary applied to be included in the program in order to advance its microRNA (miRNA) work which it began during the COVID epidemic. The company developed its DigiGENE molecular diagnostic platform using the detection of miRNAs for variant and disease detection. It will now explore the platform for the detection of other disease such as cancer and inflammatory diseases, and in addition use the biomarker discovery knowledge for new drug development.
“I am very encouraged and gratified that we were able to prove that the technology we are developing is indeed innovative and worthy of support. This support from Canada will help us accelerate our research and bring new products to the market that will have a huge health impact.”
